Advanced Emissions Solutions Announces Planned Corporate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advanced Emissions Solutions Announces Planned Corporate Restructuring

HIGHLANDS RANCH, Colo., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Advanced Emissions Solutions, Inc. (NASDAQ: ADES ) (the "Company" or "ADES") today announced that it has executed the next step of its previously announced cost containment strategy. Specifically, the Company has executed a workforce reduction plan affecting approximately 38% of the Company’s employees, many of which were servicing long-term equipment contracts that were recently completed.

Heath Sampson, President and CEO stated “As previously communicated, we continue to evaluate the changing needs of our business. The decisions made around this restructuring have been difficult, but were consistent with our plan and necessary to position the Company to succeed in a changing marketplace, meet the current and future needs of our customers and provide a platform for future growth. As a result of these actions, we expect to generate annualized expense savings of approximately $2.1 million - $2.4 million, primarily from savings in employee salaries and benefits."

About Advanced Emissions Solutions, Inc. Advanced Emissions Solutions, Inc. serves as the holding entity for a family of companies that provide emissions solutions to customers in the power generation and other industries.

ADA-ES, Inc. (“ADA”) is a wholly-owned subsidiary of Advanced Emissions Solutions, Inc. (“ADES”) that provides emissions control solutions for coal-fired power generation and industrial boiler industries. With more than 25 years of experience developing advanced mercury control solutions, ADA delivers proprietary environmental technologies, equipment and specialty chemicals that enable coal-fueled boilers to meet emissions regulations. These solutions enhance existing air pollution control equipment, maximizing capacity and improving operating efficiencies.   Our track record includes securing more than 30 US patents for emissions control technology and systems and selling the most activated carbon injection systems for power plant mercury control in North America. For more information on ADA, its products and services, visit www.adaes.com  or the ADA Blog ( http://blog.adaes.com/ ).

Clean Coal Solutions, LLC (“CCS”) is a 42.5% owned joint venture by ADA that provides ADA’s patented Refined Coal (“RC”) CyClean™ technology to enhance combustion of and reduce emissions of NOx and mercury from coals in cyclone boilers and ADA’s patent pending M-45™ and M-45-PC™ technologies for Circulating Fluidized boilers and Pulverized Coal boilers respectively.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, which provides a “safe harbor” for such statements in certain circumstances. The forward-looking statements include expectations regarding the amount of expense savings resulting from the executed workforce reduction plan and source of such savings s.  These statements are based on current expectations, estimates, projections, beliefs and assumptions of the Company’s management. Such statements involve significant risks and uncertainties. Actual events or results could differ materially from those discussed in the forward-looking statements as a result of various factors, including but not limited to, potential claims from terminated employees, unanticipated expenses related to former employee benefit payments, and disruption to business operations due to the workforce reduction. You are cautioned not to place undue reliance on such statements and to consult the Company’s SEC filings for additional risks and uncertainties that may apply to the Company’s business and the ownership of its securities. The Company’s forward-looking statements are presented as of the date made, and the Company disclaims any duty to update such statements unless required by law to do so.

Investor Contact: Alpha IR Group Nick Hughes or Chris Hodges 312-445-2870 ADES@alpha-ir.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 271

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 190

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

IONQ Achieves Record Stock Levels Amid Strong Growth Indicators

Updated Category News Views 243

IONQ Stock Reaches New Heights Recently, IONQ has made headlines as its stock skyrocketed to an unprecedented level of $47.41, marking a significant achievement for the company. With a robust market capitalization of $10.2 billion, this remarkable performance is a testament to the company's impressive growth trajectory and the strong belief investors hold in its future....

Continue Reading
Model 1 Commercial Vehicles Expands Leadership Team for Growth

Updated Category News Views 285

Model 1 Commercial Vehicles Announces Leadership Changes Model 1 Commercial Vehicles is thrilled to unveil a set of key leadership appointments aimed at enhancing its strategic direction and ensuring the company's ongoing success. These changes reflect the impressive growth trajectory the company has experienced over the past few years. Tony Matijevich Takes the Helm as...

Continue Reading
Texas Instruments: Unusual Options Trends Uncovered

Updated Category News Views 195

Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...

Continue Reading
SMCP Unveils Latest Interim Financial Report for 2025

Updated Category News Views 177

SMCP Announces Availability of Its Interim Financial Report SMCP is excited to share that its interim financial report for the six-month period ending June 30, 2025, is now available for public access. This report has been officially filed with the relevant regulatory authorities. Details on the Financial Report This financial report outlines the company's performance...

Continue Reading
Kevin O'Leary Discusses Business Leaders' Support for Trump

Updated Category News Views 159

Understanding O'Leary's Perspective on Business Leadership Kevin O’Leary, a prominent entrepreneur and investor from Shark Tank, has provided insight into the evolving relationship between business leaders and President Trump. In recent discussions, O’Leary emphasized that the admiration many tech CEOs and corporate leaders have for Trump is not solely about his tax...

Continue Reading